Panel Agrees With Lower Court: Cancer Fighting Patent Is Valid

Mealey's (May 15, 2019, 11:51 AM EDT) -- WASHINGTON, D.C. — A patented method of using the compound everolimus to treat advanced renal cell carcinoma (RCC) was confirmed as valid May 13 by the Federal Circuit U.S. Court of Appeals in a win for Novartis Pharmaceuticals Corp. and Novartis AG (Novartis, collectively) (Novartis Pharmaceuticals Corp., et al. v. West-Ward Pharmaceuticals International Ltd., No. 18-1434, Fed. Cir., 2019 U.S. App. LEXIS 14122)....